391 related articles for article (PubMed ID: 24534393)
41. [Denosumab may be a supplement to the surgical treatment of giant cell tumours of bone].
Sørensen AL; Hansen RL; Jørgensen PH
Ugeskr Laeger; 2016 Sep; 178(36):. PubMed ID: 27593237
[TBL] [Abstract][Full Text] [Related]
42. Efficacy of denosumab in joint preservation for patients with giant cell tumour of the bone.
Traub F; Singh J; Dickson BC; Leung S; Mohankumar R; Blackstein ME; Razak AR; Griffin AM; Ferguson PC; Wunder JS
Eur J Cancer; 2016 May; 59():1-12. PubMed ID: 26990281
[TBL] [Abstract][Full Text] [Related]
43. Denosumab for the treatment of giant cell tumor of the bone.
Brodowicz T; Hemetsberger M; Windhager R
Future Oncol; 2015; 11(13):1881-94. PubMed ID: 26161925
[TBL] [Abstract][Full Text] [Related]
44. An eggshell-like mineralized recurrent lesion in the popliteal region after treatment of giant cell tumor of the bone with denosumab.
Akaike K; Suehara Y; Takagi T; Kaneko K; Saito T
Skeletal Radiol; 2014 Dec; 43(12):1767-72. PubMed ID: 25052539
[TBL] [Abstract][Full Text] [Related]
45. [Treatment progress on giant cell tumors of bone].
Liang P
Zhongguo Gu Shang; 2018 Mar; 31(3):292-296. PubMed ID: 29600686
[TBL] [Abstract][Full Text] [Related]
46. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study.
Thomas D; Henshaw R; Skubitz K; Chawla S; Staddon A; Blay JY; Roudier M; Smith J; Ye Z; Sohn W; Dansey R; Jun S
Lancet Oncol; 2010 Mar; 11(3):275-80. PubMed ID: 20149736
[TBL] [Abstract][Full Text] [Related]
47. Golden bullet-denosumab: early rapid response of metastatic giant cell tumor of the bone.
Demirsoy U; Karadogan M; Selek Ö; Anik Y; Aksu G; Müezzinoglu B; Corapcioglu F
J Pediatr Hematol Oncol; 2014 Mar; 36(2):156-8. PubMed ID: 24072245
[TBL] [Abstract][Full Text] [Related]
48. Clinical outcome of recurrent giant cell tumor of the extremity in the era before molecular target therapy: the Japanese Musculoskeletal Oncology Group study.
Takeuchi A; Tsuchiya H; Ishii T; Nishida Y; Abe S; Matsumine A; Kawai A; Yoshimura K; Ueda T
BMC Musculoskelet Disord; 2016 Jul; 17():306. PubMed ID: 27448567
[TBL] [Abstract][Full Text] [Related]
49. Short-term Preoperative Denosumab With Surgery in Unresectable or Recurrent Giant Cell Tumor of Bone.
Zhang RZ; Ma TX; Qi DW; Zhao M; Hu T; Zhang GC
Orthop Surg; 2019 Dec; 11(6):1101-1108. PubMed ID: 31762217
[TBL] [Abstract][Full Text] [Related]
50. [New therapy approaches for giant cell tumors].
Panzica M; Lüke U; Omar M; Länger F; v Falck C; Krettek C
Unfallchirurg; 2014 Oct; 117(10):883-91. PubMed ID: 25274386
[TBL] [Abstract][Full Text] [Related]
51. Vertebrectomy of giant cell tumor with vertebral artery embolization: case report.
Rodrigues LM; Nicolau RJ; Puertas EB; Milani C
J Pediatr Orthop B; 2009 Mar; 18(2):99-102. PubMed ID: 19276993
[TBL] [Abstract][Full Text] [Related]
52. Role of Denosumab in Endoscopic Endonasal Treatment for Juvenile Clival Giant Cell Tumor: A Case Report and Review of the Literature.
Inoue A; Ohnishi T; Kohno S; Nishikawa M; Nishida N; Ohue S
World Neurosurg; 2016 Jul; 91():674.e1-6. PubMed ID: 27113403
[TBL] [Abstract][Full Text] [Related]
53. Giant-cell tumors of the cervical spine: case report.
Hunter CL; Pacione D; Hornyak M; Murali R
Neurosurgery; 2006 Nov; 59(5):E1142-3; discussion E1143. PubMed ID: 17143206
[TBL] [Abstract][Full Text] [Related]
54. [Clinical, radiologic and pathologic features of giant cell tumor of bone treated with denosumab].
Gong LH; Liu WF; Ding Y; Zhang W; Yang YK; Yu F; Wong GQ; Huang XY; Niu XH
Zhonghua Bing Li Xue Za Zhi; 2018 Jun; 47(6):449-454. PubMed ID: 29886590
[No Abstract] [Full Text] [Related]
55. The efficacy and safety of short-course neoadjuvant denosumab for en bloc spondylectomy in spinal giant cell tumor of bone: a preliminary report.
Tang Q; Lu J; Zhu X; Song G; Wu H; Xu H; Wang A; Wang J
Eur Spine J; 2023 Dec; 32(12):4297-4305. PubMed ID: 37318598
[TBL] [Abstract][Full Text] [Related]
56. Histopathological response to denosumab in giant cell tumours of bone - A review of 11 cases.
Kumar R; Mallya V; Mandal S; Tomar R; Khurana N; Maini L
J Cancer Res Ther; 2023; 19(3):768-772. PubMed ID: 37470608
[TBL] [Abstract][Full Text] [Related]
57. Recurrence Factors in Giant Cell Tumors of the Spine.
Ouyang HQ; Jiang L; Liu XG; Wei F; Yang SM; Meng N; Jiang P; Yu M; Wu FL; Dang L; Zhou H; Zhang H; Liu ZJ
Chin Med J (Engl); 2017 Jul; 130(13):1557-1563. PubMed ID: 28639571
[TBL] [Abstract][Full Text] [Related]
58. Interferon alfa-2b for recurrent and metastatic giant cell tumor of the spine: report of two cases.
Wei F; Liu X; Liu Z; Jiang L; Dang G; Ma Q; Dang L
Spine (Phila Pa 1976); 2010 Nov; 35(24):E1418-22. PubMed ID: 21030898
[TBL] [Abstract][Full Text] [Related]
59. The clinical approach toward giant cell tumor of bone.
van der Heijden L; Dijkstra PD; van de Sande MA; Kroep JR; Nout RA; van Rijswijk CS; Bovée JV; Hogendoorn PC; Gelderblom H
Oncologist; 2014 May; 19(5):550-61. PubMed ID: 24718514
[TBL] [Abstract][Full Text] [Related]
60. Denosumab: Current Use in the Treatment of Primary Bone Tumors.
Savvidou OD; Bolia IK; Chloros GD; Papanastasiou J; Koutsouradis P; Papagelopoulos PJ
Orthopedics; 2017 Jul; 40(4):204-210. PubMed ID: 28732103
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]